A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 23 Aug 2018
At a glance
- Drugs LY 3305677 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly
- 15 Aug 2018 Status changed from active, no longer recruiting to completed.
- 10 May 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Nov 2017 Planned End Date changed from 1 Jun 2018 to 1 Aug 2018.